Refine by
Oncology Data Articles & Analysis
21 news found
Bayer presents first Phase 1 results from its most advanced clinical Immuno-Oncology program, aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 New preclinical data on Bayer’s DGK zeta inhibitor being featured in oral presentation in New Drugs on the Horizon session New preclinical data on mutEGFR HER2 program, currently in Phase 1, ...
ByBayer AG
To facilitate these services, the company has established one of the largest and most comprehensive databases of metabolic health profiles across healthy and diseased individuals covering multiple age and gender groups as well as specific diseases in neurology, oncology, and inflammation. Lifespin, a deep data company that maps human health based on snapshots of ...
New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS) and improved key clinically relevant endpoints in patients with various types of metastatic disease burden and risk, compared to ADT with docetaxel alone Favorable safety profile of darolutamide plus ADT in combination ...
ByBayer AG
The latest round will support legal and consulting costs as well as continued expansion of its research, team, infrastructure, data acquisition and business development. 4D Path’s patented precision oncology platform unveils previously hidden data to instantly provide biomarker profiling and stratification directly from a single H&E ...
If data is still missing, xCures can query individual providers outside the network to receive complete records. Going far beyond the structured data, the xCures A.I.-powered platform abstracts knowledge from unstructured data such as physician notes and embedded images such as genomics reports. ...
ByxCures
– OCT. 4, 2022 – AIVITA Biomedical, Inc., a biotech company specializing in innovative cell applications, today announced that the Journal of Oncology Research and Therapy has published data from its completed Phase 2 glioblastoma (GBM) study which demonstrates enhanced progression-free survival (PFS). ...
The trial was conducted in patients with locally advanced or metastatic unresectable intrahepatic (inside the liver) cholangiocarcinoma (iCCA) harboringFGFR2 gene rearrangements including fusions. These data were presented as an oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. ...
PAD4 inhibition a novel pathway to inhibit tumor metastasis and tumor growth Data presented at the American Association of Cancer Research Annual Meeting 2022 Jubilant Therapeutics Inc. a biopharmaceutical company advancing small molecule precision therapeutics to address unmet medical needs in oncology and autoimmune diseases, today announced ...
“There are, unfortunately, very few treatment options available for patients with mCRPC, especially those with SCNC, for which there are no approved therapies,” said Rahul Aggarwal, M.D., Associate Director for Clinical Sciences, UCSF Helen Diller Family Comprehensive Cancer Center and Associate Professor of Hematology/Oncology, UCSF. “These ...
New Guardant Reveal™ data from interim analysis of COSMOS-CRC-01 demonstrates high performance for recurrence detection in early-stage colorectal cancer REDWOOD CITY, ...
Radiomics’ prospective, multi-center, multi-country study is aimed at validating its AI approach in the oncology space. Biopsy samples and imaging data will be collected from subjects with non-small cell lung cancer (NSCLC) to chart a non-invasive radiomics atlas of oncogenic biomarkers based on imaging features of computed tomography scans ("RATLAS"). ...
Additional patients are being enrolled, with the aim to treat up to 43 patients across the two multicenter trials (USA, UK, France). Further data will be released at a major oncology conference over the coming months and will provide the insight needed to prepare Phase II trials. ...
Using its mature multi-omics technology platform, Creative Proteomics has been devoted to providing high-quality, personalized oncology multi-omics services and reliable data support to worldwide clients for years. ...
(PsiOxus), a tumor re-engineering company, today announced that they will present key safety and translational data from their first-in-human phase 1 FORTITUDE clinical study at the European Society for Medical Oncology(ESMO) Congress 2021 this week. ...
“The ODS Medical team is very excited to welcome new investors to our efforts to provide more data-driven surgical oncology care to cancer patients,” said Christopher Kent, President & CEO of ODS Medical. ...
4D Path, creator of a patented computer-aided pan-cancer diagnostic and precision oncology platform, is pleased to announce that Dr. Craig A. Bunnell, MD, MPH, MBA, has joined the company’s distinguished advisory board. ...
To do this, MH Guide matches molecular patient data with data derived from one of the largest growing and Molecular Health-owned knowledge platforms (Dataome). ...
The company, which has raised $6.4 million in funding to date, applies its cloud-based, quantitative approach to finding the data previously hidden in an H&E biopsy image without adding extra load to the current standard of care. ...
Clinical Outcomes in Patients with High Recurrence Score Results Presented in Oral Session at ESMO 2019 Congress With Fourth Peer-Reviewed Publication, TAILORx Continues to Elevate Oncotype DX Test to a New Global Standard Genomic Health on Monday announced results from a new analysis of the Trial Assigning IndividuaLised Options for Treatment (Rx), or TAILORx, which reinforce the unique ...
Investigational compound LDK378 is a selective inhibitor of ALK[1], a target found in metastatic non-small cell lung cancer (NSCLC) Data show 60% overall response rate in 78 patients with ALK+ NSCLC taking LDK378 at 750 mg; will serve as basis for first filing in early 2014 FDA designated LDK378 as Breakthrough Therapy in March and a robust clinical development plan is ...